Benefits from the use of a pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice. Analysis of a Swiss cohort
| Autor: | Dagmar, Simon, Jann, Lübbe, Brunello, Wüthrich, Alice, Wiesner, M Monika, Weber, Emmanuel, Laffitte, Mark D, Anliker, Martin H, Schöni, Lasse R, Braathen, Peter, Schmid-Grendelmeier, Nicole, Gilgen Bobalj, Dirk, Schneider |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Adolescent Anti-Inflammatory Agents Non-Steroidal Calcineurin Inhibitors Infant Middle Aged Peptidylprolyl Isomerase Administration Cutaneous Tacrolimus Dermatitis Atopic Cohort Studies Ointments Treatment Outcome Patient Satisfaction Child Preschool Humans Female Safety Child Facial Dermatoses Aged Follow-Up Studies |
| Zdroj: | Dermatology (Basel, Switzerland). 213(4) |
| ISSN: | 1018-8665 |
| Popis: | Controlled studies established the efficacy and good tolerability of pimecrolimus cream 1% for the treatment of atopic dermatitis but they may not reflect real-life use.To evaluate the efficacy, tolerability and cosmetic acceptance of a pimecrolimus-based regimen in daily practice in Switzerland.This was a 6-month, open-label, multicentre study in 109 patients (55%or = 18 years) with atopic dermatitis. Pimecrolimus cream 1% was incorporated into patients' standard treatment protocols.The pimecrolimus-based treatment was well tolerated and produced disease improvement in 65.7% of patients. It was particularly effective on the face (improvement rate: 75.0%). Mean pimecrolimus consumption decreased from 6.4 g/day (months 1-3) to 4.0 g/day (months 3-6) as disease improved. Most patients (74.1%) rated their disease control as 'complete' or 'good' and 90% were highly satisfied with the cream formulation.The use of a pimecrolimus-based regimen in everyday practice was effective, well tolerated and well accepted by patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|